Solid Biosciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Bo Cumbo
Chief executive officer
US$918.6k
Total compensation
CEO salary percentage | 63.7% |
CEO tenure | 2yrs |
CEO ownership | 0.1% |
Management average tenure | 2yrs |
Board average tenure | 8yrs |
Recent management updates
Recent updates
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?
Nov 16We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Jul 26Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$102m |
Jun 30 2024 | n/a | n/a | -US$91m |
Mar 31 2024 | n/a | n/a | -US$90m |
Dec 31 2023 | US$919k | US$585k | -US$96m |
Sep 30 2023 | n/a | n/a | -US$91m |
Jun 30 2023 | n/a | n/a | -US$90m |
Mar 31 2023 | n/a | n/a | -US$91m |
Dec 31 2022 | US$4m | US$46k | -US$86m |
Compensation vs Market: Bo's total compensation ($USD918.55K) is below average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Bo's compensation has been consistent with company performance over the past year.
CEO
Bo Cumbo (53 yo)
2yrs
Tenure
US$918,550
Compensation
Mr. Alexander G. Cumbo, also known as Bo, serves as President, Chief Executive Officer and Director at Solid Biosciences Inc. since December 02, 2022. He serves as Independent Director of Verve Therapeutic...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chair | 4.7yrs | US$828.65k | 0.27% $ 456.4k | |
President | 2yrs | US$918.55k | 0.096% $ 160.1k | |
Co-founder | 11.9yrs | US$902.09k | 0.31% $ 514.6k | |
CFO & Treasurer | 1.9yrs | US$1.36m | 0.023% $ 38.7k | |
COO, General Counsel & Secretary | 2yrs | US$648.88k | 0.039% $ 65.2k | |
Co-Founder & Head of Patient Advocacy | no data | no data | no data | |
Chief Technology Officer | 2yrs | no data | 0.030% $ 50.7k | |
Senior Vice President of Human Resources | 2.9yrs | no data | no data | |
Chief Regulatory Officer | 2yrs | no data | 0.036% $ 59.2k | |
Head of Corporate Strategy & Business Development | 1.3yrs | no data | no data | |
Chief Medical Officer | 1.2yrs | no data | 0.027% $ 45.7k |
2.0yrs
Average Tenure
49yo
Average Age
Experienced Management: SLDB's management team is considered experienced (2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chair | 4.7yrs | US$828.65k | 0.27% $ 456.4k | |
President | 2yrs | US$918.55k | 0.096% $ 160.1k | |
Co-founder | 11.9yrs | US$902.09k | 0.31% $ 514.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Chairman of Scientific Advisory Board | 6.9yrs | no data | no data | |
Lead Independent Director | 9.1yrs | US$109.72k | 0% $ 0 | |
Independent Director | 9.1yrs | US$113.22k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
8.0yrs
Average Tenure
58yo
Average Age
Experienced Board: SLDB's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 08:06 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solid Biosciences Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Huidong Wang | Barclays |
Timothy Chiang | BTIG |
Charles Duncan | Cantor Fitzgerald & Co. |